Martin Schleef
Overview
Explore the profile of Martin Schleef including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Schmeer M, Schleef M
Methods Mol Biol
. 2014 Apr;
1143:219-40.
PMID: 24715291
For pharmaceutical applications of plasmid DNA, either direct or indirect, certain quality standards are required. Whereas for direct gene transfer into human "Good Manufacturing Practice" (GMP) grade is mandatory, for...
22.
Walther W, Schmeer M, Kobelt D, Baier R, Harder A, Walhorn V, et al.
Hum Gene Ther Clin Dev
. 2013 Sep;
24(4):147-53.
PMID: 24067054
The great interest for naked plasmid DNA in gene therapy studies is reflected by the fact that it is currently used in 18% of all gene therapy trials. Therefore, validation...
23.
Viefhues M, Wegener S, Rischmuller A, Schleef M, Anselmetti D
Lab Chip
. 2013 Jun;
13(15):3111-8.
PMID: 23760065
We present a prototype nanofluidic device, developed for the continuous-flow dielectrophoretic (DEP) fractionation, purification, and quality control of sample suspensions for gene vaccine production. The device consists of a cross...
24.
Kobelt D, Schleef M, Schmeer M, Aumann J, Schlag P, Walther W
Mol Biotechnol
. 2012 Apr;
53(1):80-9.
PMID: 22467123
Plasmid DNA is frequently used particularly for nonviral gene therapy. Conventional plasmid DNA contains bacterial backbone and resistance gene sequences, as well as immunogenic CpG motifs. These components are not...
25.
Magnusson T, Haase R, Schleef M, Wagner E, Ogris M
J Gene Med
. 2011 Jul;
13(7-8):382-91.
PMID: 21721074
Background: Plasmid-based gene therapy approaches often lack long-term transgene expression in vivo as a result of silencing or loss of the vector. One way to overcome these limitations is to...
26.
Schleef M, Schmeer M
Pharm Unserer Zeit
. 2011 Jun;
40(3):220-4.
PMID: 21698611
No abstract available.
27.
Schleef M, Blaesen M, Schmeer M, Baier R, Marie C, Dickson G, et al.
Curr Gene Ther
. 2010 Nov;
10(6):487-507.
PMID: 21054244
After some decades of research, development and first clinical approaches to use DNA vectors in gene therapy, cell therapy and DNA vaccination, the requirements for the pharmaceutical manufacturing of gene...
28.
Wooddell C, Subbotin V, Sebestyen M, Griffin J, Zhang G, Schleef M, et al.
Hum Gene Ther
. 2010 Oct;
22(2):225-35.
PMID: 20942645
Various plasmids were delivered into rodent limb muscles by hydrodynamic limb vein (HLV) injection of naked plasmid DNA (pDNA). Some of the pDNA preparations caused significant muscle necrosis and associated...
29.
Schleef M, Blaesen M
Methods Mol Biol
. 2009 Jul;
542:471-95.
PMID: 19565918
Developments in gene therapy, cell therapy, and DNA vaccination require a pharmaceutical gene vector that, on one hand, fulfils the properties to express the encoded information--preferably at the right place,...
30.
Mayrhofer P, Schleef M, Jechlinger W
Methods Mol Biol
. 2009 Jul;
542:87-104.
PMID: 19565897
A large number of cancer gene therapy clinical trials are currently being performed that are attempting to evaluate novel approaches to eliminate tumor cells by the introduction of genetic material...